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The automatic implantable cardioverter-defibrillator was 
implanted in 270 patients because of life-threatening 
arrhythmias over a 7 year period. There was a history of 
sustained ventricular tachycardia or fibrillation, or both, in 
96% of these patients, 80% had one or more prior cardiac 
arrests and 78% had coronary artery disease as their 
underlying diagnosis. The average ejection fraction was 
34%, and 96% of these patients had had an average of 3.4 
antiarrhythmic drug failures per patient before defibril- 
lator implantation. There were four perioperative deaths 
and eight patients had generator infection or generator 
erosion, or both, during the perioperative period or during 
long-term follow-up. Concomitant antiarrhythmic drug 
therapy was given to 69% of patients. 
Shocks from the device were given to 58% of patients, 
Patients who have survived out of hospital cardiac arrest or 
who have recurrent sustained ventricular tachycardia have a 
high long-term total and sudden death mortality rate when 
their arrhythmias cannot be controlled with antiarrhythmic 
drug therapy (1,2). Previous reports (3-6) have shown a 
remarkably low short-term sudden death mortality rate in 
patients receiving the automatic implantable cardioverter- 
defibrillator (AICD). Although most centers have reported 
an acceptable rate of complications, others have emphasized 
certain problems with the device (7). There is undoubtedly a 
“learning curve” that exists for the implantation of these 
devices, with fewer complications and problems occurring 
as a center gains additional experience. 
In the near future, there will be tremendous changes in 
the types of devices being implanted, the lead configurations 
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and 20% received “problematic” shocks. The device was 
removed from 16 patients during long-term follow-up for a 
variety of reasons. There were 7 sudden cardiac deaths and 
30 nonsudden cardiac deaths, 18 of which were secondary 
to congestive heart failure. The actuarial incidence of 
sudden death, total cardiac death and total mortality from 
all causes was 1% ,7 % and 8 %, respectively, at I year, and 
4%, 24% and 26% at 5 years. 
The automatic implantable cardioverter-defibrillator 
nearly eliminates sudden death over a long-term follow-up 
period in a high risk group of patients. It has an acceptable 
rate of complications or problems, or both, and most late 
deaths in these patients are nonsudden and of cardiovascu- 
lar origin. 
(,I Am Co11 Cardiol1989;13:1353-61) 
and defibrillating waveforms used and, over the next few 
years, in patient selection. Devices will soon include fea- 
tures such as backup bradycardia pacing, antitachycardia 
pacing and low energy cardioverting capabilities (S-IO). 
Lead configurations will include three epicardial patch lead 
systems, transvenous catheters (11) and transvenous cathe- 
ters coupled with subcutaneous patches (12). In addition to 
the standard monophasic truncated exponential waveform 
now utilized, devices with sequential pulses (l3,14) and 
biphasic pulses (15-17) will become available. These newer 
devices may be better suited than the current device to treat 
patients with more frequent episodes of arrhythmia recur- 
rence. and the indications for implantation may therefore 
broaden. There have been no significant changes in patient 
selection criteria for the currently available defibrillator from 
the inception of the program in 1980. Although there have 
been improvements in the device and implant techniques, 
they have been relatively minor compared with changes that 
will likely occur during the next few years. Therefore, it 
seems an appropriate time to report our long-term experi- 
ence with the automatic implantable cardioverter-defibril- 
01989 by the American College of Cardiology 0735.1097!89/$3..FO 
1354 WINKLE ET AL. JACC Vol. 13, No. 6 
EXPERIENCE WITH THE IMPLANT May 1989: 1353-61 
lator. In the present study, we report our seven year 
experience with regard to clinical observations, complica- 
tions, modifications of implantation techniques over time 
and long-term survival. 
Methods 
Study patients. This study describes our experience with 
273 consecutive patients undergoing surgery for implanta- 
tion of the automatic implantable cardioverter-defibrillator 
between March 2, 1981 and March 2, 1988. This experience 
represents the personal experience of one of the authors 
(R.W.), and includes 88 implantations at Stanford University 
Medical Center, Stanford and 185 at Sequoia Hospital, 
Redwood City, California. Our early experience after the 
first 70 implantations was reported in detail in 1985 (3). All 
patients undergoing initial implantation at our centers are 
included even if they were subsequently followed up at other 
implanting centers. Patients undergoing initial implantation 
elsewhere and followed up by our center are not included in 
this analysis. All patients signed written informed consent 
before device implantation, and implantation protocols were 
approved by the Human Subjects Committee of Stanford 
Medical Center and the Institutional Review Board of Se- 
quoia Hospital for all implantations done before Food and 
Drug Administration approval of the device. 
defibrillator implant as a therapeutic option if they had poor 
ventricular function and repetitive forms on noninvasive 
monitoring, or if they had the long QT syndrome or primary 
ventricular fibrillation. When an implantable defibrillator 
was contemplated for a patient, the patient and his or her 
family underwent extensive preoperative education, includ- 
ing provision of audiovisual and written materials, extensive 
sessions with specially trained nurses as well as ample time 
to discuss the therapy with one or more physicians (18). 
Patient selection and preoperative evaluation. Patients 
were offered the automatic implantable cardioverter- 
defibrillator as a therapeutic alternative if they had at least 
one cardiac arrest caused by ventricular tachycardia or 
ventricular fibrillation, or both, or had recurrent episodes of 
sustained life-threatening ventricular tachycardia. Patients 
were excluded from implantation if their cardiac arrest was 
due to acute myocardial infarction, antiarrhythmic or other 
drug toxicity or severe electrolyte abnormalities. A small 
number of patients had either syncopal episodes that were 
unmonitored or known to be due to nonsustained ventricular 
tachycardia with sustained hypotensive ventricular tachy- 
cardia inducible at electrophysiologic study, or had a familial 
sudden death syndrome with inducible sustained ventricular 
tachycardia at electrophysiologic study. 
Except for unusual circumstances, all patients underwent 
complete cardiac evaluation, including right and left heart 
catheterization, coronary and left ventricular angiography, a 
complete baseline intracardiac electrophysiologic study and 
an extensive period of in-hospital telemetry monitoring. 
Patients with inducible sustained ventricular tachyarrhyth- 
mia underwent serial electrophysiologic studies in an effort 
to find an antiarrhythmic drug that would prevent arrhythmia 
induction. Patients whose arrhythmia could not be induced 
while they were receiving antiarrhythmic medication were 
not offered a defibrillator implant. Patients with a single out 
of hospital cardiac arrest whose arrhythmia was not induc- 
ible at baseline electrophysiologic study were offered a 
All patients with episodes of nonsustained ventricular or 
supraventricular tachycardia that could trigger the commit- 
ted device had these arrhythmias controlled with anti- 
arrhythmic drugs. Patients with extremely frequent episodes 
of sustained ventricular tachycardia had these episodes 
controlled with antiarrhythmic medication or were excluded 
from device implantation, as were most patients whose rate 
of ventricular tachycardia was ~140 beatslmin. After early 
1985, most patients with significant organic heart disease 
were routinely treated with digoxin to slow episodes of atria1 
fibrillation, even if they had never had this arrhythmia. 
Treadmill exercise tests were routinely performed early in 
our experience to evaluate peak sinus rate, but they were not 
performed routinely after 1984. Review of previous sponta- 
neously occurring ventricular tachyarrhythmias, in-hospital 
monitoring data and the arrhythmias induced at electrophys- 
iologic study was utilized to select the cutoff rate of the 
implanted device. Whenever possible, antiarrhythmic ther- 
apy was discontinued shortly before defibrillator implanta- 
tion to avoid myocardial depression during surgery. 
Device and lead selection. Devices implanted before July 
1982 (Patients 1 to 5) were the original automatic implantable 
defibrillator (AID) models, which sensed only sinusoidal 
ventricular tachycardia or fibrillation. From July 1982 until 
October 1986, the automatic implantable cardioverter- 
defibrillator (AICD) was used, after which time the Ventak 
model 1520 was utilized. All devices were manufactured by 
Intec Systems or Cardiac Pacemakers, Inc. Ninety-nine 
percent of all devices used were rate only/high energy 
models. The first four patients received spring and patch 
leads made of silver tinsel. All other cardioverting- 
defibrillating leads were made with drawn braised strands of 
conducting material. For Patients 1 to 13, only spring-patch 
lead configurations were utilized. For Patients 14 to 109, 
spring-patch lead systems were the standard configuration 
but, if unacceptable defibrillation thresholds were obtained, 
two patch lead systems were utilized. After Patient 109, 
nearly all patients received large patch-large patch configu- 
rations. Epicardial screw-in leads manufactured by Medtron- 
ic Corp., Daig Corp. or Cardiac Pacemakers, Inc. were used 
in most patients. Transvenous endocardial sensing leads 
were utilized only when patients had unacceptable R wave 
amplitudes at several ventricular sites or when the sensing 
leads needed late revision because of insulation or conductor 
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malfunction, or both, of previously implanted epicardial 
leads. 
Surgical technique. Except for the first two patients who 
underwent median sternotomy. all patients undergoing only 
automatic implantable cardioverter-defibrillator implanta- 
tion had this done by a limited left thoracotomy performed 
for patch lead and epicardial sensing lead placement. After 
September 1984, a double lumen endotracheal tube was 
utilized to deflate the left lung transiently to facilitate poste- 
rior patch placement. When one patch lead was used in 
conjunction with the superior vena cava spring, it was the 
cathode and was positioned near the apex of the heart. When 
two patch leads were used. the cathode was positioned on 
the posterolateral left ventricular wall and the anode over the 
anterior right ventricular walls. When superior vena cava 
spring leads or transvenous endocardial leads were utilized. 
they were inserted percutaneously through the left subcla- 
vian vein. The distal ends of all leads were tunneled below 
the costal margin to the deep subcutaneous space in the mid 
left abdomen and connected to the generator, which was 
placed in a deep subcutaneous pocket. Patients undergoing 
patch implantation by means of a median sternotomy had the 
left cathodal patch placed near the inferoapical left ventricle 
and the right patch placed along the right atrial border. 
All patients with significant (>70%) coronary artery le- 
sions supplying viable myocardium had the lesions bypassed 
or (less frequently) treated with percutaneous transluminal 
angioplasty. Most patients undergoing other major cardiac 
procedures in addition to defibrillator implantation had a two 
stage operation, with the patch leads implanted initially at 
the time of their primary cardiac surgical procedure and the 
generator placed after recovery from surgery. All patients 
undergoing endocardial resection had patch leads left in 
place pending the outcome of postoperative electrophysio- 
logic studies. In these patients, an automatic implantable 
cardioverter-defibrillator generator was placed if ventricular 
tachycardia occurred spontaneously or remained inducible 
after endocardial resection. Patch leads were sutured to the 
outside of the parietal pericardium. Only when defibrillation 
thresholds were unacceptable were the patches placed inside 
the pericardium or was the polarity of the shocking leads 
reversed. 
Most patients undergoing generator changes for depleted 
batteries were admitted on the morning of the generator 
change and discharged the next day. Prophylactic cephalo- 
sporin antibiotic agents were given to patients before early 
1985. Since then, all nonallergic patients undergoing either 
new system implantation or generator changes underwent 
preoperative povidone iodine (Betadine) showers and re- 
ceived prophylactic antibiotics using both a cephalosporin 
and vancomycin. 
Intraoperative testing. After Patient 14. extensive defi- 
brillation threshold testing (19) was performed routinely for 
new implants and generator changes utilizing the InteciCPI 
external cardioverting defibrillator (ECD) box or the Ventri- 
tex HVS-02 testing device. Ventricular fibrillation was in- 
duced in all patients. utilizing either alternating (AC) current 
or bursts of rapid pacing with a cycle length of IO to 20 ms. 
Testing of cardioversion thresholds was not routinely carried 
out at the time of device implantation. Patients undergoing a 
two stage procedure who had a prolonged cardiopulmonary 
bypass time during their primary cardiac operation had only 
limited initial testing to be certain that I5 J was effective, 
with extensive defibrillation threshold evaluation at the time 
of generator implantation. In order for a “defibrillation 
threshold” to be acceptable, 25 J was required to reliably 
provide a “clean defibrillation” on essentially every test. It 
was also desired to have 20 J be nearly uniformly effective, 
and I5 J was expected to be effective approximately half the 
time. Lower energies were routinely tested. with 25 J rescue 
shocks being given for ineffective low energy defibrillations. 
If the defibrillation threshold was considered unaccept- 
able and the patient had a spring-patch lead system, it was 
upgraded to a two patch system. For patch-patch lead 
systems. an unacceptable defibrillation threshold led to 
further attempts at lead repositioning. placement of the 
patches inside the pericardium or reversal of defibrillating 
lead polarity. If these maneuvers failed to result in an 
acceptable defibrillation threshold. the device was not im- 
planted. the leads were left in place and the patient returned 
to the operating room approximately 7 to IO days later when 
the leads had a chance to approach “chronic” thresholds. If 
the defibrillation threshold remained unacceptable. a deci- 
sion was made regarding the advisability of device implan- 
tation, or the patient was considered for a reoperation to try 
a different patch placement. When a satisfactory defibrilla- 
tion threshold was obtained with the external testing equip- 
ment, the permanently implanted leads were attached to the 
AICD generator and the arrhythmia was induced one or 
more additional times to be certain that the device to be 
implanted would effectively terminate the arrhythmia with a 
single shock. 
Pacemaker evaluations. Only bipolar pacemakers were 
utilized in conjunction with the automatic implantable car- 
dioverter-defibrillator. Care was taken to avoid double 
counting of atrial and ventricular pacing stimuli or a ventric- 
ular pacing stimulus and its evoked local potential if this 
occurred >I50 ms beyond the pacing spike. All implanted 
pacemakers were chosen to have maximal programmability 
of pacemaker output. Testing was performed to avoid this 
potential double counting by evaluating the pacemaker when 
programmed to its maximal output, and the defibrillator in 
the electrophysiologic test mode. In addition, the pacemaker 
was generally programmed to values of heart rate less than 
half the automatic implantable cardioverter-defibrillator rate 
cutotT so that if double counting did occur, the defibrillator 
would not be triggered. To be certain that the pacemaker did 
not cause undersensing of a sustained ventricular tachy- 
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arrhythmia by causing the automatic gain control circuits of 
the defibrillator to “lock-in” on the pacing spike and ignore 
the underlying ventricular tachyarrhythmia, arrhythmia ep- 
isodes were induced with the pacemaker programmed to 
maximal output in an asynchronous pacing mode. Finally, 
pacemakers were ultimately programmed to the lowest volt- 
age output consistent with a reasonable margin of safety for 
atria1 or ventricular capture, or both. 
Postoperative care. All newly implanted automatic im- 
plantable cardioverter-defibrillators were kept inactive dur- 
ing the early postoperative period. Antiarrhythmic medica- 
tions, if indicated, were restarted in the postoperative 
period. Encainide was not given to any patient receiving an 
automatic implantable cardioverter-defibrillator because of 
the possibility of increasing defibrillation thresholds (20). 
Patients undergoing therapy with other type IC drugs always 
underwent generator testing while taking the drug being 
used. Patients undergoing a staged procedure had no further 
testing of the device. Patients with an initial complete system 
implant had follow-up electrophysiologic studies at approx- 
imately 5 to 7 days postoperatively. The clinical arrhythmia 
was induced at this study on the antiarrhythmic medication 
to be given on a long-term basis. The device was left in the 
active mode after this study. A 24 h ambulatory electrocar- 
diographic (ECG) recording was obtained during the first 24 
h after all newly implanted devices were placed in the active 
mode. Patients were generally discharged the day after 
device activation unless other medical conditions required 
them to stay in the hospital. Operative deaths were defined 
as those occurring within 30 days of the initial implantation 
or during the initial hospitalization if it was >30 days and the 
death was thought to be a direct complication of the surgery. 
Long-term follow-up. Two hundred twenty-three of the 
273 patients were followed up primarily by us in conjunction 
with each patient’s personal cardiologist. The remaining 50 
patients were followed up primarily at other implanting 
centers. Follow-up evaluation was by direct communication 
with the patient or patient’s physician, or both, mailed 
questionnaires or data obtained from the Cardiac Pacemaker 
Inc. computer data base. Patients were seen every 2 months 
for the first 14 months after each new generator was placed 
and 1 month thereafter. At each visit a physical examination, 
charge time to evaluate battery status and the number of 
shocks delivered by the device were recorded. Patients were 
generally not reevaluated extensively for single defibrillator 
shocks; they were hospitalized promptly when a barrage of 
defibrillator shocks developed. For intermittent but frequent 
discharge of devices, continuous 24 h ambulatory ECG 
recordings were obtained until 1984. After that time, gener- 
ous use was made of transtelephonic devices with a memory 
loop to determine the cause of frequent discharges. Once the 
cause of the defibrillator shocks was confirmed, drug therapy 
was modified to prevent these discharges. 
Throughout the study, aggressive therapy was given for 
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Figure 1. Distribution of ages of 270 patients receiving an automatic 
implantable cardioverter-defibrillator. The average age was 58.2 + 
11.8 years. 
underlying congestive heart failure and, since 1986, the oral 
inotrope vasodilator enoximone has been utilized for pa- 
tients, followed up primarily by us, who failed to respond to 
diuretic drugs and vasodilators. Patients with uncontrolled 
heart failure who were otherwise appropriate candidates 
were referred for cardiac transplantation. 
For the purposes of this study, sudden cardiac death was 
defined as witnessed instantaneous death. All unwitnessed 
out of hospital deaths were considered to be sudden. All 
patients whose deaths were classified as due to congestive 
heart failure were under observation in a medical facility at 
the time of death and died after a progressive course of 
worsening heart failure unresponsive to maximal medical 
therapy. Deaths were considered as arrhythmic but nonsud- 
den when they occurred in-hospital as a result of uncon- 
trolled ventricular tachyarrhythmias. 
Statistical analysis. All data are presented as mean values 
+ SD unless otherwise specified. Life table analysis of 
survival was evaluated by the Kaplan-Meier method. 
Results 
Patient characteristics. The average age of the patients 
undergoing defibrillator implantation was 58.2 of: 11.9 years 
(range 12 to 77) (Fig. 1). Two hundred seventeen of the 270 
patients were male and 53 were female. The underlying heart 
disease is summarized in Table 1. Ejection fraction, avail- 
able for 200 patients (73%), had a median value of 34 + 15% 
(Fig. 2). The primary underlying cardiac arrhythmia is sum- 
marized in Table 2. Fifty-three patients (20%) had not expe- 
Table 1. Underlying Cardiac Disease in 270 Patients 
Coronary artery disease 
Dilated cardiomyopathy 
Valvular 
Primary electrical 
Long QT syndrome 
Hypertrophic cardiomyopathy 
Other (hypertension 2, Marfan’s syndrome 2, right ventric- 
ular dysplasia 2, congenital 1, myasthenia gravis 1) 
211 (78.2%) 
22 (8.1%) 
13 (4.8%) 
7 (2.6%) 
6 (2.2%) 
3 (1.1%) 
8 (3.0%) 
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Figure 2. Distribution of ejection fractions of 200 patients receiving 
an automatic implantable cardioverter-defibrillator. Ejection frac- 
tion averaged 34%: it was ~40% in 70% of patients. 
Figure 3. Number of device shocks per patient. The average num- 
ber was 4.8 per patient. 
rienced prior cardiac arrest, 136 (50%) had had a single 
cardiac arrest and 81 (30%) had had more than one cardiac 
arrest (average = 1.5 cardiac arrests per patient). At baseline 
electrophysiologic study, 23 1 patients (86%) had sustained 
ventricular tachyarrhythmias reliably induced. Ten patients 
(4%) had ventricular tachyarrhythmias induced, but induction 
was not reliable enough for serial drug testing; in 27 patients 
(IO%), tachyarrhythmias were not inducible, and 2 patients 
(1%) had no baseline electrophysiologic study. Eighty-six 
patients (32%) had undergone previous cardiac surgery, in- 
cluding coronary artery bypass grafting alone in 53 patients, 
prosthetic valve replacement in 7 patients, bypass surgery 
plus valve replacement in 10 patients, aneurysm resection 
with bypass grafting in 12 patients and other procedures in 4 
patients. Two hundred sixty-nine patients (96%) had had at 
least one antiarrhythmic drug failure clinically or at elec- 
trophysiologic study, and the average number of drug failures 
for the entire group was 3.4 t 1.8 per patient. 
Operative procedure. Two hundred seventy patients re- 
ceived an automatic implantable cardioverter-defibrillator 
generator; three patients did not undergo generator implan- 
tation despite operation for lead placement because of ele- 
vated defibrillation thresholds (see later discussion). The 
Table 2. Problematic Device Shocks in 270 Patients 
Sinus tachycardia (one nonfatal arrest) 
SVT including atrial fibrillation 
NSVT 
VT 
NSVTIVT 
Unknown 
Misdirection (one nonfatal arrest) 
Sensing lead fracture 
Screw caps off 
Generator malfunction 
7 
13 
3 
Pacemaker interaction I 
Total 55 (20.5%) 
NSVT = nonsustained ventricular tachycardia; SVT = supraventricular 
tachycardia: VT = ventricular tachycardia. 
initial shocking lead configuration was large patch-large 
patch in 183 patients (68%). spring-small patch in 71 patients 
(26%). spring-large patch in 9 patients (3%), large patch- 
small patch in 5 patients (2%) and small patch-small patch in 
2 patients (I %). The sensing lead configuration was epicar- 
dial screw-in leads in 242 patients (90%) and endocardial 
sensing leads in 27 patients (10%). One patient received only 
the AID device, which required no sensing leads. A total of 
189 patients (70%) received the AICD generator as the only 
operation performed. Eighty-one patients (30%) underwent 
AICD system implantation as part of a concomitant cardiac 
surgical procedure. These procedures included coronary 
bypass surgery alone in 54 patients, endocardial resection 
alone in 8, valve replacement alone in 2, endocardial resec- 
tion plus bypass surgery in 12, endocardial resection plus 
plus valve replacement in 2 and other operations in 3. 
Among the patients receiving the AICD in conjunction with 
additional cardiac surgery, the generator was implanted at 
the time of initial surgery in 21 patients and at a second 
procedure before hospital discharge in 60. Subsequent gen- 
erator replacements were for the standard indications of 
battery depletion, excessive capacitor charge times or de- 
vice malfunction. Only a single generator was implanted in 
148 patients, two generators in 75, three generators in 36, 
four generators in IO and five generators in 1 patient. 
Concomitant pacemakers. A total of 29 patients (11%) 
had a bradycardia pacemaker used simultaneously with the 
AICD. These included 10 (VW) pacemakers, 16 (DDD) 
pacemakers, 1 (AAI) pacemaker and 2 Intermedics Inter- 
Tach antitachycardia pacemakers. One patient with the 
antitachycardia pacemaker has terminated a number of 
episodes of slow ventricular tachycardia with the antitachy- 
cardia device. The other patient had significant interactions 
between the InterTach and the AICD at the time of implan- 
tation, and the combination was a clinical failure. 
Defibrillator shocks. A total of 156 patients (58%) re- 
ceived shocks from their AICD generator (Fig. 3). For most 
patients receiving occasional infrequent shocks. no effort 
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was made to determine whether the shocks were “appro- 
priate” or “inappropriate” because our previous experience 
indicated this was difficult on clinical grounds. A total of 55 
patients (20%), however, had episodes of problematic 
shocks; the causes for these are listed in Table 2. Once the 
cause for the problematic shocks was identified, all but five 
patients had them controlled by changes in drug therapy. 
Lead problems. Eight (10%) of 80 patients receiving 
superior vena cava spring leads had a total of 12 episodes of 
complications. These included five instances of lead migra- 
tion and seven instances of lead fracture. One sudden death 
occurred when a device failed to terminate ventricular 
tachycardia/fibrillation because of the migration of a spring 
lead. Eight patients (2%) experienced problems with 462 
patch leads. One of these was a crinkled patch lead that 
resulted in late elevation of the defibrillation threshold and 
the lead was replaced. Several other patients have crinkled 
patches on chest X-ray study, but defibrillation thresholds 
remain acceptable. One patient had an insulation break near 
the header that was successfully repaired. Six patients had a 
lead conductor fracture in the abdomen. Repair was success- 
ful in two patients and required repeat thoracotomy with 
patch lead replacement in four patients. One of the patch 
lead fractures was detected when a patient had an out of 
hospital cardiac arrest that the device did not terminate and 
from which he was successfully resuscitated by paramedics. 
The other patch lead fractures were diagnosed at the time of 
elective generator replacement. Six patients (1%) experi- 
enced problems with 511 sensing leads. One patient had a 
bad signal whose precise cause was never determined. In 
two patients with insulation breaks, the leads were replaced 
with new endocardial lead systems. One patient had an 
epicardial screw-in lead accidently cut at the time of gener- 
ator change, and two patients received inappropriate shocks 
(the sensing lead was found to be loose in the header in one 
patient, and the screw caps had been inadvertently left off at 
the time of original generator implantation in the other). 
Three of the four patients with the originally used silver 
tinsel leads had these changed. Two patients had spring 
leads and patches electively replaced because of a known 
history of a high incidence of lead fracture with this system. 
One patient had the spring lead electively replaced and 
subsequently had the patch lead replaced when it became 
infected. 
System infections/erosions. Six patients had AICD system 
infection, one had erosion with subsequent infection and 
another had erosion without infection. For the six system- 
induced infections not due to erosion, three occurred at the 
time of new implantation, two at the time of generator 
change and one when a lead was repositioned. One of the 
seven infections was due to Serratia and was treated with 
generator removal and antibiotics, with the patch lead left 
intact. The remaining infections were due to Staphylococcus 
uureus, and one patient with this infection died from over- 
whelming sepsis. In the remaining five patients, the entire 
AICD system was removed. Three of the five patients had 
the system reimplanted at a new surgical procedure after full 
recovery from the infection. 
Operative complications. There were four postoperative 
deaths (1.5%). One of these occurred in a patient with 
amiodarone pulmonary toxicity preoperatively who devel- 
oped adult respiratory distress syndrome postoperatively. A 
second was due to perforation of the superior vena cava at 
the time of pacemaker implantation, which was performed 
immediately after placement of an automatic defibrillator. A 
third death was related to amiodarone toxicity postopera- 
tively: the fourth occurred in a patient who had intractable 
ventricular tachycardia postoperatively that required emer- 
gency endocardial resection on the fourth postoperative day 
and who subsequently died of overwhelming sepsis related 
to the endocardial resection. Other perioperative complica- 
tions included an infected chest tube site in one patient, 
staphylococcal sepsis caused by a central venous pressure 
catheter in one patient and a pacemaker infection that 
required revision of the pacemaker generator in one patient. 
Four patients experienced a perioperative cerebrovascular 
accident, none of which resulted in permanent sequelae. 
There were two pocket hematomas related to anticoagulant 
therapy. Two patients were taken back to the operating 
room because of bleeding related to their patch leads. 
Elevated defibrillation thresholds. A total of seven pa- 
tients had an unacceptable defibrillation threshold at the time 
of implantation or at a 7 to 10 day follow-up assessment of 
defibrillation threshold, or both. Five (6%) of these patients 
were in our first group of 88 patients and only 2 (I %) were in 
the last group of 182 patients. In three of these patients, 
including one who underwent reoperation with a three patch 
configuration, the generator was never implanted because it 
was believed that it would be totally nonfunctional. In one 
patient, the device was removed before hospital discharge 
because it was found to accelerate ventricular tachycardia to 
fibrillation that it could not terminate. Two of these seven 
patients had good defibrillation thresholds achieved by re- 
operation. One (the first patient known to receive two 
patches) was reoperated on the day after the initial opera- 
tion, and successful defibrillation thresholds were achieved 
with use of two patches; the other patient required mitral 
valve replacement 2 years after the original implantation, 
and underwent lead revision at the time of sternotomy, with 
excellent defibrillation thresholds. One patient whose ven- 
tricular fibrillation was terminated approximately 50% of the 
time with 25 J had the device left in place. Two patients had 
subsequent late elevation of previously acceptable defibril- 
lation thresholds. One of these patients, with a spring-patch 
lead system, refused reoperation for revision to a patch- 
patch system and had the device removed after it failed to 
work for sustained ventricular tachycardia on several occa- 
sions. The other patient had a crinkled patch lead and 
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Table 3. Concomitant Drug Therapy in 270 Patients 
No. IQ) 
Antiarrhythmic drugs 
Amiodarone alone 
Amiodarone plus ir type I agent 
Procainamide 
Sotalol 
Propafenone 
Mexiletine plus a type I agent 
Mexiletine alone 
Quinidine 
Tocainide 
Flecainide 
Lorcainide 
Other 
Total 
AV node blocking drugs 
Digoxin alone 
Digoxin plus a beta-blocker 
Digoxin plus a calcium channel blocker 
Beta-blocker alone 
Calcium channel blocker alone 
Calcium channel blocker plus a beta-blocker 
Total 
61 (‘1.6) __ 
IO (3.7) 
22 (8.1, 
22 tx.1, 
I8 tn.71 
I3 (4.X) 
I? (4.4) 
IO (3.7) 
9 (3.1) 
3 (I.11 
3 (I.11 
3 (I.11 
1% (68.9) 
IO? (37.X) 
II (4.1) 
II (4.1) 
19 (7.0) 
3 (7.1) 
I (0.4) 
147 (54.5) 
SUDDENDEATHS 
Number of Patients 
08 1 
000 
1 2 3 4 5 6 7 
A YtXlS 
TOTAL DEATHS 
Number of Pat~enfs 
AV = atrioventricular 
underwent reoperation with revision of the crinkled patch 
lead with restoration of excellent defibrillation thresholds. 
Concomitant drug therapy. One hundred eighty-six pa- 
tients (69%) received one or more antiarrhythmic drugs to 
suppress nonsustained or sustained tachyarrhythmias that 
might cause frequent device discharges, and atrioventricular 
(AV) node blocking drugs were given to 147 patients (55%) 
(Table 3). 
Long-term follow-up. There was a total of 40 deaths 
among the patients undergoing continuous treatment with 
the AICD. Seven of these deaths were sudden, including two 
in patients who were believed to have battery depletion (one 
on the basis of glass corrosion and one because of reaching 
generator end of life) and one patient who experienced 
sudden death and was not resuscitated by his defibrillator 
because of spring lead migration. Three of the 40 deaths 
were noncardiac as a result of pneumonia in one patient, a 
primary respiratory arrest in one patient and exsanguination 
from end stage lung cancer in one patient. The cause of death 
among the 30 patients with nonsudden cardiac death was 
slow progressive congestive heart failure in 18 patients, 
cerebrovascular accident in 3, clotted prosthetic valve in 1 
patient, postoperative death in 4, infection after generator 
change in 1 patient, subsequent myocardial infarction in 1, 
subacute electromechanical dissociation in 1 and uncon- 
trolled slow ventricular tachycardia in 1. Except for one 
patient who refused hospitalization despite severe end stage 
congestive heart failure and the patient with end stage lung 
cancer, all patients classified as having a nonsudden death 
Figure 4. Survival of patients receiving an automatic implantable 
cardioverter-defibrillator. A, Actuarial survival rate with regard to 
sudden death. B. Total survival rate, including operative deaths (see 
Table 4). 
died under direct medical observation, generally after a 
prolonged downhill hospital course. 
Figure 4 shows the actuarial survival curves for these 
patients. Exact yearly survival data are listed in Table 4. 
Six patients experienced nonfatal out of hospital cardiac 
arrest, and u’ere not successfully resuscitated by their de- 
vice. Two of these episodes were induced by the device in an 
outpatient medical setting; one occurred in the patient with a 
crinkled patch who was undergoing a treadmill exercise test 
when the device fired and precipitated a malignant ventric- 
ular arrhythmia that it could not terminate, and the other 
occurred during a magnet test with a misdirected initiating 
ventricular fibrillation that the device could not terminate 
because of a device malfunction. Both patients were suc- 
cessfully resuscitated by medical personnel in attendance. 
Of the four additional nonfatal out of hospital cardiac ar- 
rests. one was due to complete heart block and a second was 
a result of documented cardiac asystole. The device appro- 
priately did not fire for either of the bradyarrhythmic arrests. 
A third episode occurred in the patient who subsequently 
was found to have a fractured patch lead. In this patient, the 
1360 WINKLE ET AL. JACC Vol. 13, No. 6 
EXPERIENCE WITH THE IMPLANT May 1989:135Ml 
Table 4. Kaplan-Meier Actuarial Mortality Rate in 270 Patients 
1 Year 2 Years 3 Years 
(n = 188) (n = 113) (n = 69) 
4 Years 
(n = 51) 
5 Years 
(n = 12) 
Sudden death 
Cardiac (nonsudden) 
All cardiac 
Total 
0.9% 3.1% 4.4% 4.4% 4.4% 
6.2% 13.0% 13.9% 15.3% 20.3% 
7.0% 15.6% 17.8% 19.1% 23.8% 
7.7% 16.3% 18.4% 19.7% 26.2% 
device had attempted to terminate the arrhythmia with four 
shocks, but these were obviously unsuccessful. The fourth 
patient, who received a series of shocks that failed to abort 
the cardiac arrest, was successfully externally resuscitated 
by bystanders. The device functioned normally when it was 
subsequently tested at electrophysiologic study. The reason 
for its failure to abort the cardiac arrest is unknown. 
Among the 270 patients receiving an AICD generator, 16 
living patients were withdrawn from the series. Four of these 
patients had the device explanted because it proved to be 
ineffective; one of these had one of the original defibrillator 
units that could not sense ventricular tachycardia, one had 
ventricular tachycardia that accelerated to ventricular fibril- 
lation that could not be terminated, one had a high defibril- 
lation threshold at implantation and one had late elevation of 
the defibrillation threshold. Three patients asked to have the 
device removed because they thought it was no longer 
needed, three underwent subsequent cardiac transplantation 
and three did not have the device replaced after it became 
infected; in three other patients it was removed because their 
personal physician believed it was no longer needed. One 
patient withdrawn alive from this series was lost to follow-up 
study. Three of the 19 patients who never had the device 
placed because of high defibrillation thresholds or were 
withdrawn from the series alive experienced subsequent 
sudden cardiac death. 
Discussion 
Improvements during the past 7 years. This report de- 
scribes our 7 year experience with the automatic implantable 
cardioverter-defibrillator (AICD). It considerably expands 
on the number of patients (70) we had previously reported on 
(3) and gives a much longer-term follow-up assessment. 
Over the past 7 years, our indications for implantation of this 
device, the patients in whom it has been used, the number of 
antiarrhythmic drug failures and the use of other therapies 
have not changed remarkably. However, several changes 
have occurred with regard to implantation technique and 
follow-up of these patients, and our experience contains an 
ongoing “learning curve.” Very early in our experience, it 
became apparent that the devices needed to sense ventricu- 
lar tachycardia as well as fibrillation, and the original auto- 
matic implantable defibrillator (AID) generator was modified 
to include cardioverting capabilities. The high incidence of 
silver tinsel lead fractures led to the development of sturdier 
leads with a much lower failure rate. Failure to defibrillate 
with the implanted device led to the utilization of extensive 
defibrillation threshold testing (19) and two large patch leads 
rather than the original spring-patch lead configuration for 
delivering the defibrillating shocks (21). We have incorpo- 
rated into our operative routines more extensive antibiotic 
prophylaxis to protect against Staphylococcus aureus. Be- 
cause of the occurrence of rather unpleasant AICD shocks 
for nonsustained ventricular tachyarrhythmias and supra- 
ventricular tachycardia, we have made generous use of 
antiarrhythmic drugs and AV node blocking drugs to prevent 
these shocks. Finally, improved therapy for congestive heart 
failure has become possible through the use of the angioten- 
sin-converting enzyme inhibitors and the oral inotrope eno- 
ximone. Finally, the skills of the investigators have im- 
proved remarkably in the management of patients with end 
stage congestive heart failure. 
Follow-up mortality and complications. The present study 
demonstrates that the extremely low 1 and 2 year sudden 
death rates previously reported (3,4,6) in patients receiving 
the automatic implantable cardioverter-defibrillator continue 
to be maintained for as long as 5 years. During the longer 
follow-up period, the largest number of deaths are nonsud- 
den and of cardiovascular origin, with more than half of 
these a result of progressive congestive heart failure. The 
longer follow-up period and larger number of patients have 
uncovered relatively few problems and complications not 
previously appreciated, but have served to provide a better 
assessment of their frequency of occurrence. 
Device improvements. The knowledge obtained during 
the past 7 years has already resulted in some device im- 
provements. This experience also provides data on which to 
base recommendations for improvements needed in future 
devices. The shocks given for nonsustained supraventricular 
and ventricular tachycardia could be eliminated if the device 
had programmable sensing times and was a noncommitted 
device that did not fire if an arrhythmia terminated before the 
defibrillating shocks had been delivered. Patient acceptance 
would probably be improved even further if the device 
provided antitachycardia pacing and programmability for 
shock output to reduce the discomfort from the shocks. The 
large number of generator changes required because of short 
battery life would be substantially reduced with greater 
battery longevity. The >lO% incidence of need for a sepa- 
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rate concomitanr backup bradycardia pacemaker as well as 
the two documented bradyarrhythmic aborted cardiac ar- 
rests indicate that backup bradycardia pacing would be a 
desirable feature in these devices. The ability to reliably 
distinguish SUPI aventricular from ventricular tachycardia 
would also reduce the number of unnecessary shocks. De- 
spite the limitations of the present device. its remarkable 
success in preventing sudden death supports its widespread 
use in high risk patients. 
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